SAR-20347

SAR-20347 is a preclinical small-molecule dual inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), developed by Sareum in partnership with SRI International. It selectively targets TYK2 and JAK1 over other Janus kinase family members (JAK2 and JAK3). By blocking these kinases, SAR-20347 inhibits downstream STAT phosphorylation and suppresses signaling pathways activated by cytokines such as IL-12, IL-23, IL-22, and type I interferons. In preclinical studies, SAR-20347 has demonstrated therapeutic efficacy in animal models of autoimmune and inflammatory diseases, including psoriasis, inflammatory bowel disease, lupus, rheumatoid arthritis, and multiple sclerosis.

Other names

2-(2-Chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-oxazolecarboxamide2-(2-chloro-6-fluorophenyl)-5-((4-(morpholine-4-carbonyl)phenyl)amino)oxazole-4-carboxamideSAR 20347SAR20347SAR-20347